Shilpa Medicare is locked at its upper circuit limit of RS. 939.10, rising by 44.70 points or 5.00% from its previous close of RS. 894.40 on the BSE.

The stock opened at RS. 891.00 and recorded a high of RS. 939.10 and a low of RS. 880.00 during the session. So far, 17,446 shares have been traded on the counter.

A BSE group 'T' stock with a face value of RS. 1, Shilpa Medicare touched a 52-week high of RS. 1003.20 on June 16, 2025, and a 52-week low of RS. 530.50 on April 7, 2025. Over the past week, the stock’s high and low were RS. 939.10 and RS. 846.05, respectively. The company’s current market capitalization stands at RS. 9,153.23 crore.

The promoter holding in the company is at 44.23%, while institutions and non-institutions hold 18.52% and 37.25%, respectively.

Shilpa Medicare recently received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) classification for its Unit VI at Dabaspet, Bengaluru, Karnataka, from the U.S. Food and Drug Administration (USFDA). The GMP inspection was conducted between October 24-30, 2024. This facility manufactures, packages, tests, stores, and distributes complex dosage forms such as Oral Dissolving Films and Transdermal Systems.

The Bengaluru unit is already approved by EMA (Europe), MHRA (UK), SFDA (Saudi Arabia), and TGA (Australia). It currently supplies Oral Film products to the US and other markets, while Transdermal products have been filed in the European market.

Shilpa Medicare is known for producing and exporting high-quality Active Pharmaceutical Ingredients (APIs), fine chemicals, intermediates, herbal products, and specialty chemical products using advanced technology while adhering to international standards.